Initially reported in 2014 by Demirci et al., the authors presented a case in which PSMA PET/CT revealed more metastatic sites in a patient with ccRCC compared to FDG PET/CT, demonstrating higher sensitivity [20]. This evidence concerns the gene FOLH1 and nonpapillary renal cell carcinoma.